Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and…
- Trial name
- HALO (NCT00528905)
- Testing
- AZD3480
- Where
- 80 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia, Schizo Affective Disorder
Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider Engagement
The effective treatment of schizophrenia is very challenging due to a number of factors. These include issues such as poor engagement with treatment plans and care providers, limited contacts with providers due to under-resourced…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- NCT04602741
- Testing
- A4i Intervention
- Where
- Canada
- Volunteers
- 91 people
- Sponsor
- Centre for Addiction and Mental Health
Clozapine, Parkinson's Disease (PD)
Clozapine-related Immunodeficiency in Parkinsons Disease
Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia.
- Conditions
- Clozapine, Parkinson's Disease (PD), Immunodeficiency, Psychosis
- Trial name
- CLOZIDPD (NCT06634641)
- Testing
- blood test
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Schizophrenia
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
- Trial name
- NCT03121586
- Testing
- Pimavanserin
- Where
- 161 sites in United States, Argentina and 12 more
- Volunteers
- 995 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Anti-inflammatories and Adolescent Schizophrenia
A double-blind controlled trial assessing the efficacy of anti-inflammatories on symptoms and cognition of adolescents with schizophrenia
- Trial name
- NCT04020588
- Testing
- Celecoxib 200mg, Minocycline 100mg
- Where
- Mexico
- Volunteers
- 90 people
- Sponsor
- Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
Cognitive Remediation in Early Phase Psychosis
The purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychosis NOS
- Trial name
- NCT01546467
- Testing
- Cognitive remediation
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Schizophrenia Disorders
An Integrated Neurophysiological Approach Toward the Early Detection of Psychiatric Disorders
Schizophrenia (SCZ) is a severe neuropsychiatric disorder characterized by cognitive decline, social withdrawal, and positive symptoms such as hallucinations and delusions.
- Trial name
- NCT06886945
- Testing
- Audio-Visual Perceptual Tasks
- Where
- Italy
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- Trial name
- NCT01074632
- Testing
- Lurasidone HCl
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy [CET]) and an affect regulation (Personal Therapy [PT]) intervention for 50 individuals with schizophrenia that misuse cannabis.
- Trial name
- NCT01292577
- Testing
- CET/PT, Treatment as Usual
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pittsburgh
Psychosis
Compassion Focused Therapy for Distressing Experiences
This study aims to develop and test the feasibility of a new therapy called Compassion Focused Therapy (CFT) for psychosis. This therapy helps people with psychosis manage distressing experiences by building internal feelings of…
- Trial name
- NCT02733575
- Testing
- Compassion Focused Therapy
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- King's College London
Schizophrenia
tDCS, Stress and Risk for Schizophrenia
An exacerbated response to stress mediated by activation of the Hypothalamo-Pituitary-Adrenocortical (HPA) axis is thought to play an important role in the onset, worsening and relapse of schizophrenia.
- Trial name
- 3S (NCT03217357)
- Testing
- Transcranial stimulation in direct current
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Hôpital le Vinatier
Schizophrenia
PEARL Schizophrenia Maintenance
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
- Trial name
- NCT01435928
- Testing
- Lurasidone
- Where
- 75 sites in United States, France and 5 more
- Volunteers
- 676 people
- Sponsor
- Sumitomo Pharma America, Inc.
Mental Disorders, Schizophrenia
A System for Preference Assessment in Mental Health
It is important that individuals with serious mental illness make informed choices among alternative healthcare treatments based on their preferences.
- Conditions
- Mental Disorders, Schizophrenia, Overweight, Obesity
- Trial name
- SPA (NCT02183844)
- Testing
- Psychosocial Weight Intervention
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
Treatment with prednisolone can be used as a proof of concept to investigate the possibility of immune modulation as a treatment for schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder NOS
- Trial name
- NCT02949232
- Testing
- Prednisolone
- Where
- 4 sites in Belgium, Denmark and 1 more
- Volunteers
- 42 people
- Sponsor
- UMC Utrecht
Schizophrenia, Schizoaffective Disorder
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
- Trial name
- NCT01242371
- Testing
- Probiotic Supplement
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizoaffective
Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
This is a 15 week trial to determine (1) the safety and tolerability of varenicline when used for smoking cessation/reduction in individuals with schizophrenia; (2) if treatment with varenicline affects the symptoms of…
- Conditions
- Schizophrenia, Schizoaffective, Psychosis
- Trial name
- NCT00702793
- Testing
- Varenicline
- Sponsor
- University of British Columbia
Cocaine Dependence, Cannabis Dependence
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
Background: Several studies of risk perception have demonstrated a common bias known as unrealistic optimism, in which individuals feel they are less likely than other people to experience unpleasant or harmful events in their…
- Conditions
- Cocaine Dependence, Cannabis Dependence, Schizophrenia
- Trial name
- NCT01031563
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.